NCT05746754 (CSI ProLong) is a NA clinical trial of CSI in Leptomeningeal Metastasis, sponsored by University of Aarhus.

Who is sponsoring NCT05746754?

NCT05746754 is sponsored by University of Aarhus.

What drugs are being tested in NCT05746754?

Interventions in NCT05746754: CSI.

What condition does NCT05746754 study?

NCT05746754 studies Leptomeningeal Metastasis.

Is NCT05746754 still recruiting?

NCT05746754 is currently recruiting now. Last updated 6 April 2025.

Last reviewed 2025-04-06 · How we verify

NCT05746754: CSI ProLong

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Proton Cranio-spinal Irradiation for Leptomeningeal Metastasis

Recruiting now NA Last updated 6 April 2025

What this trial tests

NA trial testing CSI in Leptomeningeal Metastasis in 50 participants. Currently enrolling.

Timeline

1 November 2023

Primary endpoint
1 April 2026

1 April 2031

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 November 2023
Primary completion	1 April 2026
Estimated completion	1 April 2031
Sites	2 locations across Denmark

Drugs / interventions tested

Conditions studied

Leptomeningeal Metastasis — all drugs for Leptomeningeal Metastasis →

Sponsor

University of Aarhus

Who can join

18 and older, any sex, with Leptomeningeal Metastasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Leptomeningeal metastasis is a rare but serious complication to cancer, with a grave prognosis. No efficient treatment exists. Recent data suggest that craniospinal radiotherapy lead to superior survival and CNS control compared to focal photon radiotherapy. We want to offer Danish patients the new treatment, but within a protocol, as this is new data with an new treatment principle

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions.
Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, et al · · 2024 · cited 42× · PMID 38902944 · DOI 10.1093/neuonc/noae103
Leptomeningeal Metastases in Melanoma Patients: An Update on and Future Perspectives for Diagnosis and Treatment.
Steininger J, Gellrich FF, Engellandt K, Meinhardt M, et al · · 2023 · cited 11× · PMID 37511202 · DOI 10.3390/ijms241411443
Radiotherapy and Systemic Treatment for Leptomeningeal Disease.
Frechette KM, Breen WG, Brown PD, Sener UT, et al · · 2024 · cited 5× · PMID 39200256 · DOI 10.3390/biomedicines12081792

Verify or expand the search:

Other recruiting trials for Leptomeningeal Metastasis

Currently open trials in the same condition.

NCT07348965 — Pulsatile High-dose Furmonertinib in EGFR-mutant NSCLC With Leptomeningeal Metastasis · NA · recruiting
NCT07398599 — Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metast · NA · recruiting
NCT06296745 — Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. · Phase 2 · recruiting
NCT07098806 — Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases · Phase 1 · recruiting
NCT06984523 — Study of Craniospinal Irradiation With Linac Based Volumetric Modulated Arc Therapy (VMAT) for Patients With Leptomening · NA · active not recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05746754 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 6 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05746754.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing